Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tryptophan biosynthetic pathway in mycobacteria, such as Mycobacterium tuberculosis, is a critical metabolic pathway that enables the organism to synthesize tryptophan de novo from chorismate. This pathway involves several enzymes, including TrpE, TrpD, TrpC, PriA, TrpB, and TrpA. Its essentiality for survival within host cells, especially under nutrient-limited conditions, makes it a promising target for novel antitubercular drugs. Humans lack this pathway, increasing the selectivity of potential inhibitors. Disruption of the pathway leads to avirulence.
Inhibition of tryptophan biosynthesis, leading to tryptophan starvation and bacterial death
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tryptophan Biosynthesis Enzymes in Mycobacteria (Trp Enzymes (Mycobacteria)).